

Prostaglandins

Vitamin D derivatives(19) Pneumocandins(4) APIs & Intermediates [Custom Synthesis](#)

Prostaglandins

[Latanoprost \[HOT\]](#)

[Travoprost](#)


[Bimatoprost](#)

[Dinoprostone \(Prostaglandin E2\)](#)

[Alprostadil \(Prostaglandin E1\)](#)

Travoprost, 157283-68-6

Travoprost



[CAS](#)

[Molecular](#)

[Formula](#)

[Molecular](#)

[Weight](#)

[System](#)

[Name](#)

[Assay](#)

[View via](#)

[file](#)

Specification

Appearance	Colorless or pale yellow oil	Complies
Identification	(1) by HPLC (2) by TLC	Complies
Optical rotation	+52.0° to +58.0°	54.7°
Water	Not more than 1.0%	0.79%
Limit of Ethyl acetate	Not more than 0.5%	Not detected
Residual substance	Travoprost acid: N.M.T:0.2% Epoxide derivative: N.M.T:0.4% 15-epi diastereomer: N.M.T:0.1% 5,6-trans Travoprost: N.M.T:3.5% 15-keto derivative: N.M.T:0.3% Any single impurity: N.M.T:0.1% Total impurities: N.M.T:4.0%	Not detected Not detected Not detected Not detected Not detected Not detected
Residual solvents	Acetonitrile: N.M.T:0.04% Ethanol: N.M.T:0.5% n-Hexane: N.M.T:0.05% IPA: N.M.T:0.5% Dichloromethane: N.M.T:0.06%	Not detected 0.068% Not detected 0.48% Not detected
Assay	96.0% to 102.0%	98.7%

Related Prostaglandins

[Latanoprost \[HOT\]](#)

[Travoprost](#)

[Bimatoprost](#)

[Dinoprostone \(Prostaglandin E2\)](#)

[Alprostadil](#)

Patent Disclaimer

PD1

Products protected by valid patents are not covered. The presence of such products constitutes a patent infringement. Products and technologies that are available in the market and products may be developed or produced for

- commercial aim.
- PD2 Sales of products are limited to those allowed for commercial purposes. The quantity of products sold includes Research and development quantities.
- PD3 the buyer assumes responsibility of all patents for the product(s) of Lano's Pharmaceutical Co., Ltd.
- PD4 R&D use in accordance with (1) 35 USC 271(e)(1); (2) Article 30 of the Japanese Patent Law in Japan; (3) Section 25(1) of the German Patent Act in Germany; (iv) Section 60, Paragraph 5b of the German Patent Act in Germany; Sections 55.2(1) and 55.2(6) and other comparable provisions of the Japanese Patent Law; (5) Section 68B of the Patents Act of 1953 in the United Kingdom or any law of same by the Statutes Amendment Bill of 2004 in the United Kingdom; (6) any law as may be or become applicable in the future; (7) any laws and rules as may apply in various other countries.

Friend link: www.meilipharma.com